17 Results for "

FGFR1-4

" in MedChemExpress (MCE) Product Catalog:
Products (17)

17 Results for "FGFR1-4" in MCE Product Catalog:

  • Targets Recommended:
95
95 Publications Verification
Cat. No.: HY-10981
CAS No.: 417716-92-8
Purity:  99.75%
Synonyms: E7080
Target:  

VEGFR FGFR PDGFR c-Kit RET

Research Areas:  

Cancer

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
95
95 Publications Verification
Cat. No.: HY-10981A
CAS No.: 857890-39-2
Purity:  99.86%
Synonyms: E7080 mesylate
Target:  

VEGFR FGFR PDGFR RET c-Kit

Research Areas:  

Cancer

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
8
8 Cited Publications
Cat. No.: HY-100818
CAS No.: 1448169-71-8
Purity:  99.65%
Synonyms: TAS-120
Target:  

FGFR

Research Areas:  

Cancer

Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) .
1
1 Cited Publications
Cat. No.: HY-101768
CAS No.: 1802929-43-6
Purity:  99.78%
Target:  

FGFR c-Fms

Research Areas:  

Cancer

PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively .
Cat. No.: HY-10981S
CAS No.: 2264050-65-7
Purity:  99.59%
Synonyms: E7080-d4
Lenvatinib-d4 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
Cat. No.: HY-156632
CAS No.: 2750709-91-0
Purity:  99.53%
Synonyms: KIN-3248
Target:  

FGFR

Research Areas:  

Cancer

Resigratinib (KIN-3248) is an irreversible and orally active covalent inhibitor of FGFR1-4 that effectively inhibits wild-type and drug-resistant mutations (such as FGFR2 V565F, FGFR3 V555M). Resigratinib covalently binds to the Cys492 site of FGFR, blocks the FGFR signaling pathway, inhibits tumor cell proliferation and induces apoptosis. Resigratinib can be used for the study of FGFR2/3-driven solid tumors (such as cholangiocarcinoma and bladder cancer) .
Cat. No.: HY-10981R
CAS No.: 417716-92-8
Synonyms: E7080 (Standard)
Research Areas:  

Cancer

Lenvatinib (Standard) is the analytical standard of Lenvatinib. This product is intended for research and analytical applications. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
Cat. No.: HY-100818R
CAS No.: 1448169-71-8
Synonyms: TAS-120 (Standard)
Research Areas:  

Cancer

Futibatinib (Standard) is the analytical standard of Futibatinib. This product is intended for research and analytical applications. Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) .
Cat. No.: HY-133980A
Purity:  95.54%
Target:  

Drug Metabolite

Research Areas:  

Cancer

O-Demethyl Lenvatinib hydrochloride is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET. Lenvatinib shows potent antitumor activities .
Cat. No.: HY-133980
CAS No.: 417717-04-5
Target:  

Drug Metabolite

Research Areas:  

Cancer

O-Demethyl Lenvatinib is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
Cat. No.: HY-10981S1
Synonyms: E7080-d5
Lenvatinib-d5 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
Cat. No.: HY-10981AR
CAS No.: 857890-39-2
Synonyms: E7080 mesylate (Standard)
Research Areas:  

Cancer

Lenvatinib (mesylate) (Standard) is the analytical standard of Lenvatinib (mesylate). This product is intended for research and analytical applications. Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
Cat. No.: HY-10981S2
Synonyms: E7080-15N,d4
Lenvatinib- 15N,d4 is 15N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
Cat. No.: HY-168653
Target:  

FGFR

Research Areas:  

Cancer

FGFR-IN-15 (compound 18i) is a pan-FGFR inhibitor with potently inhibitory activity against FGFR1-4. .
Cat. No.: HY-170919
CAS No.: 3025799-28-1
Target:  

FGFR

Research Areas:  

Cancer

FGFR2/3-IN-2 (compound 10) is an orally active FGFR2 and FGFR3 inhibitor. FGFR2/3-IN-2 inhibits FGFR2 and FGFR3 with IC50s of 3.7 nM and 31.2 nM (preincubation time 1 h), respectively. FGFR2/3-IN-2 spares FGFR1/4 and other kinases without causing diarrhea and serum phosphate elevation in vivo. FGFR2/3-IN-2 induces tumor stasis or regression in the SNU-16 gastric cancer model .
Cat. No.: HY-172922
Target:  

FGFR

Research Areas:  

Cancer

Arg-IN-1 is a selective Arginine (Arg)-targeting covalent inhibitor with IC50s of 9.7 nM and 30.4 nM for FGFR2 and FGFR3,respectively. Arg-IN-1 has the potential to avoid FGFR1/4-targeted toxicity as well as conquer acquired on-target resistance, potential for FGFR-targeting cancer therapy .
Cat. No.: HY-101768R
CAS No.: 1802929-43-6
Research Areas:  

Cancer

PRN1371 (Standard) is the analytical standard of PRN1371 (HY-101768). This product is intended for research and analytical applications. PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively .
  • 1